Platelet Activation Affecting the Rate of Vascular Access Patency

Korea University

Status: Unknown

Conditions: Platelet Activation; Hemodialysis Fistula Thrombosis

Treatments: Biological: platelet activation factors

Study type: Observational

Funder types: Other

Identifiers

NCT05165797

KoreaUAnamH

Details and patient eligibility

About

In the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the vascular patency rate, but there are not many studies on the use of antiplatelet agents in the dialysis approach. The basis for use is insufficient. There is a lack of research on whether maintaining a state in which platelet activation is suppressed is helpful in improving dialysis access patency. Therefore, we conducted this study to determine whether the degree of platelet activation affects the patency of vascular access.

Enrollment: 30 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients 19 years of age or older who are undergoing hemodialysis during renal replacement therapy
• Patients undergoing arteriovenous fistula formation and hemodialysis to the affected area
• Patients who have the ability and willingness to consent to participate in the clinical study, have signed the consent form in accordance with the appropriate procedures, and can visit and participate in the clinical study as planned

Exclusion criteria

• Patients who failed to start hemodialysis with an arteriovenous fistula within 3 months
• Patients who have had stent implantation or surgery during the study period due to cardiovascular disease
• Patients with severe hepatic impairment
• Patients with coagulopathy and liver disease associated with clinically significant bleeding risk
• Patients with clinically significant bleeding or bleeding risk
• Patients who underwent artificial heart valve replacement requiring anticoagulant administration
• Patients with pulmonary embolism who are hemodynamically unstable or require thrombolysis or pulmonary embolization.
• Pregnant and lactating women